Optimising outcome measures in cognitive drug trials for schizophrenia
Digital assessment technologies continue to hold the potential to revolutionise pro-cognitive trials in schizophrenia. These advancements could continue to streamline data collection, improve trial accuracy and ultimately accelerate the development of effective treatments to address unmet patient need.
